Welcome to Biotech Mission from Alabama
Didier Malherbe Vice President Public Affairs
October 2014 2 UCB’s vision 3 UCB: reinventing itself, leveraging a solid heritage
1972: A new state-of-the-art 2006: UCB Beyond acquires German 1928: Emmanuel R&D center in 1990s: approval of ® pharma company Janssen establishes Braine-l’Alleud, Keppra , Combine leadership Schwarz Pharma UCB in Brussels Belgium a novel in antibody research anti-epileptic & chemistry expertise to better treat severe diseases
1952: UCB discovers Atarax® U.S. license awarded to Pfizer 2004: UCB acquires British biotech company 1980s: UCB Celltech registers its novel Launch of Cimzia®, antihistamine Vimpat® & Neupro® ® Zyrtec (CVN) 1936: UCB enters the United States
1928 1936 1952 1972 1980 1990s 2004 2006 2008-2010 Beyond s Chemical Group Primary Care Pharma Specialty Bio-pharma 2004, a Year of Transformation
INVEST DIVEST
Celltech Surface Specialties
Revenues € 0.5 billion Headcount 1,900 Revenues € 1.4 billion Headcount 2,800
Films
A Biopharma Leader
Revenues € 2.3 billion Headcount 8,500
4 5 UCB: A patient-centric biopharma leader
Focusing on severe diseases in Immunology and the Central Nervous System
2013 revenue: €3.4 billion
Approximately 8,500 employees globally
Operations in more than 40 countries
R&D Spend: 25+% of revenue
Listed on Euronext
Stephanie, living with rheumatoid arthritis 6 A turning point Launching of three medicines for patients with severe diseases
Rheumatoid arthritis Epilepsy adjunctive • Launched in the U.S. Parkinson’s disease therapy (May 2009) • Launched in U.S. • Launched in Europe • Launched in Europe (July 2012) (October 2009) (September 2008) • Launched in Europe Crohn’s disease • Launched in the (June 2009) • Launched in the U.S. U.S. (June 2009) Restless legs (April 2008) syndrome Ankylosing Spondylitis, • Launched in U.S. Psoriatic Arthritis (July 2012) • Launched in the U.S. • Launched in Europe (October 2013) (June 2009)
For full prescribing information, visit www.ucb-usa.com. 7 Rich early and late-stage pipeline
Phase 1 Phase 3 Filing Phase 2 /Approved
CDP7657 Vimpat® romosozumab Vimpat® NBE, Lupus Epilepsy PGTCS PMO Epilepsy mono in U.S. Start Phase 3 FDA decision early 2015 Cimzia® H2 2014 Juvenile RA UCB7665 UCB4940 NBE, immuno NBE, immuno epratuzumab Phase 1 ‘POC light’ SLE started achieved
Vimpat® epilepsy paed. UCB5857 NCE, immuno Start Vimpat® Phase 2 early 2015 Adj. ther. Asia
Vimpat® Epilepsy mono EU
brivaracetam Adj. epilepsy POS Positive headline Phase 3 results Submission early 2015 8 Continued focus on 5 main growth drivers
Cimzia®, Vimpat®, Neupro®
Emerging markets value sustainable and Superior
Mature product portfolio
Schematic picture UCB MARKET CAPITALISATION IN € Bio (EURONEXT) 16 14 14
12 9.9 10 9.4 7.9 8 5.8 5.7 5.9 6 5.5 5.4 4.4 4.3 4.7 4
2
0 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
9
R&D investors in Belgium The 2013 EU Industrial R&D investors in Belgium
800
700
600
500 (Mio EUR) (Mio 400
300
200
100
-
http://iri.jrc.ec.europa.eu/reports.htm 10
R&D investment per employee, in top EU companies (EU scoreboard 2013) mployees, in top EU companies 90.000
80.000
70.000
60.000
50.000
40.000 R&D R&D per (EUR) employees
30.000
20.000
10.000
0.000
Top 50 EU companies by R&D/Employees, the 2013 industrial R&D investment scoreboard European Commission, Dec 2013 11 Open innovation at UCB: more than 400 partnerships in the world
Research Partnerships oncology
Romosozumab
Bone loss disorders
Neurocom Neurodegenerative diseases CNS research CNS Research University Lausanne Regional Grants
Federal Ministry of Education 'NeuroAllianz‘ and Research consortium Public support
Research Partnerships Cyclofluidic drug discovery Technology Strategy Board
12 Global presence but Belgium as main «hub»
Brussels: Headquarters Braine: research hub in neurology
Strategic production site
> 140 cooperation agreements with most Belgian universities Bio pilot plant
About 2 000 people working in Belgium
13 14 UCB in the U.S.
Approximately 1,800 U.S.-based employees 600+ field-based U.S. Headquarters, Smyrna, GA suburb of Atlanta 47 acres, six buildings (includes 4 other tenants); 336 personnel Clinical Development, Raleigh, NC Manufacturing facility, Seymour, IN Manufactures Venlafaxine and all products for UCB’s generic division (Kremers Urban)